Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from CSL ( (AU:CSL) ) is now available.
CSL Limited has provided an update on its ongoing on-market share buy-back program involving its ordinary fully paid shares listed on the ASX. The company reported a cumulative total of 4,175,454 shares repurchased before the previous trading day and a further 58,274 shares bought back on the previous day, reflecting continued execution of its capital management strategy.
The latest notification, dated 12 March 2026, is part of a series of daily buy-back disclosures that began after the initial program announcement in August 2025. Regular buy-back activity of this scale can signal management’s confidence in CSL’s long-term value, potentially support earnings per share, and may influence the stock’s trading dynamics and capital structure to the benefit of existing shareholders.
The most recent analyst rating on (AU:CSL) stock is a Hold with a A$153.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biotechnology company listed on the ASX, best known for developing and manufacturing biopharmaceutical products such as vaccines, plasma therapies and specialty medicines. Its primary markets include healthcare systems in developed economies, with a focus on treatments for serious and chronic illnesses that require advanced biologic solutions.
Average Trading Volume: 1,172,741
Technical Sentiment Signal: Sell
Current Market Cap: A$70.13B
See more insights into CSL stock on TipRanks’ Stock Analysis page.